Symptomatic ICH and outcomes in patients after IV tPA: a business of risk or risky business?

Neurology. 2011 Jul 26;77(4):315-6. doi: 10.1212/WNL.0b013e3182267bea. Epub 2011 Jun 29.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Cerebral Hemorrhage / complications
  • Cerebral Hemorrhage / drug therapy*
  • Clinical Trials as Topic / methods
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Injections, Intravenous
  • Risk Factors
  • Stroke / complications
  • Stroke / drug therapy*
  • Tissue Plasminogen Activator / administration & dosage
  • Tissue Plasminogen Activator / therapeutic use*

Substances

  • Fibrinolytic Agents
  • Tissue Plasminogen Activator